Breaking News

Daiichi Sankyo Invests 15B Yen in ADC Mfg. Expansion

To optimize and enhance ADC manufacturing capabilities at three plants in Japan

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Daiichi Sankyo Co., Ltd. is making an initial 15 billion yen investment to optimize and enhance its manufacturing capabilities to support its antibody drug conjugate (ADC) pipeline.    The company will build new and refurbish manufacturing lines at three of its manufacturing plants in Japan. These improvements will expand the production of fully synthesized ADCs and help to ensure a stable supply for future investigational and commercial use.   Antibody drug conjugates (ADCs) are a type of t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters